• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Corthera

edit

Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera’s lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

Milestones

edit

• 
  Corthera received $23M in Series C funding. (12/20/07)
  Posted 7/13/09 at 9:10pm via basmedical.com
• 
  Corthera was acquired by Novartis for $620M. (12/23/09)
  Posted 1/12/10 at 5:38am via novartis.com

Videos

Screenshots

edit

Above: Corthera
Uploaded: 7/14/09

Sources

1. Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure (novartis.com) [edit]
2. Corthera Closes $23 Million Financing Round (basmedical.com) [edit]